Self-Care of Diabetic Nephropathy

Uoon Jeong Shin

doi:10.4093/jkd.2019.20.3.176

Journal List > J Korean Diabetes > v.20(3) > 1134495

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Shin: Self-Care of Diabetic Nephropathy

Information Desk

J Korean Diabetes 2019;20(3):176-180.

Published online: 10 January 2019

DOI: https://doi.org/10.4093/jkd.2019.20.3.176

Self-Care of Diabetic Nephropathy

Uoon Jeong Shin

Diabetes Center, Asan Medical Center, Seoul, Korea

Corresponding author: Uoon Jeong Shin Diabetes Center, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea, E-mail: wear13@hanmail.net

Received 27 July 2019 Accepted 31 July 2019

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Early intervention in patients with diabetes may slow the progression of kidney disease, and early recognition of renal impairment is critical to achieving optimal patient outcomes. Annual screening for the presence of albuminuria in diabetic patients is necessary to prevent diabetic neuropathy. Selection of the appropriate medication to control blood glucose and blood pressure is also important. In addition, however, patients should be willing to manage themselves to overcome diabetic kidney disease through lifestyle changes such as diet, smoking, and weight management, and restrictions on private therapies.

Keywords: Diabetic nephropathies, Self care

References

1. Korean Diabetes Association. The diabetes. 4th ed.Seoul: Korea Medical Book Publishing Company;2011.

2. American Diabetes Association. Standards of medical care in diabetes–2010. Diabetes Care. 2010; 33(Suppl 1):S11–61.

3. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. McFarlane P, Gilbert RE, MacCallum L, Senior P. Chronic kidney disease in diabetes. Can J Diabetes. 2008; 37(Suppl 1):S129–36.

4. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007; 49(2 Suppl 2):S42–154.

5. Korean Diabetes Association. Medical treatment manual for diabetes-practice of dietetic therapy doctor need to know. Seoul: Korean Diabetes Association;2011. p27.

6. Lee YJ, Kim YG. Special review: the current status of diabetic nephropathy in Korea. Korea J Med. 2009; 77:667–9.

7. James MT, Grams ME, Woodward M, Elley CR, Green JA, Wheeler DC, de Jong P, Gansevoort RT, Levey AS, Warnock DG, Sarnak MJ. CKD Prognosis Consortium. A metaanalysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury. Am J Kidney Dis. 2015; 66:602–12.

8. Diabetes Control and Complications Trial Research Group. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulindependent diabetes mellitus. N Engl J Med. 1993; 329:977–86.

9. de Boer IH. DCCT/EDIC Research Group. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014; 37:24–30.

10. Wanner Ch, Inzucchi SE, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375:1801–2.

11. Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377:2099.

12. Mann JFE, Ørsted DD, Buse JB. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017; 377:2197–8.

13. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T. SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375:1834–44.

14. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329:1456–62.

15. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345:861–9.

16. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000; 355:253–9.

17. Korean Diabetes Association. Treatment guideline for diabetes. Korean Diabetes Association;2019. p. 45.

18. Bentata Y, Karimi I, Benabdellah N, Alaoui FE, Haddiya I, Abouqal R. Does smoking increase the risk of progression of nephropathy and/or cardiovascular disease in type 2 diabetic patients with albuminuria and those without albuminuria? Am J Cardiovasc Dis. 2006; 6:66–9. eCollection 2016.

19. Hill CJ, Cardwell CR, Maxwell AP, Young RJ, Matthews B, O'Donoghue DJ, Fogarty DG. Obesity and kidney disease in type 1 and 2 diabetes: an analysis of the National Diabetes Audit. QJM. 2013; 106:933–42.

20. Morales E, Valero MA, León M, Hernández E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 2003; 41:319–27.

TOOLS

Similar articles